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ABSTRACT
Background: Pre-labour rupture of membranes (PROM) at term is a common event 
whose management varies from centre to centre. The practice at the Kenyatta National 
Hospital (KNH) for patients with PROM at term is to initiate delivery of the patient soon 
on admission with intravenous oxytocin, if there are no contraindications to vaginal 
delivery. However, in PROM at term, if the cervix is not ripe,vaginal administration 
of prostaglandin pessaries for cervical ripening is not possible when there is active 
draining of liquor, thus use of intravenous oxytocin may take a very long time or fail 
all together.
Oral misoprostol at low doses has been found to be a safe and effective agent for labour 
induction in numerous studies carried out in the developed world, where there are better 
resources for monitoring of labour. None of the studies has been carried out in Kenya, 
a limited resource country. Therefore, there is a need to determine the effectiveness 
and safety of oral misoprostol solution at the KNH, a limited resource set up.
Objective: To determine the effectiveness and safety of 2-hourly 20 mcg oral misoprostol 
solution compared to the standard intravenous oxytocinin labour induction in mothers 
with pre-labour rupture of membranes at term at the Kenyatta National Hospital.
Design: An unblinded randomised clinical trial. 
Setting: Kenyatta National Hospital Labour Ward Unit.
Participants: Eighty three pregnant women with pre-labour rupture of membranes 
at term without an indication for Caeserian section were consented and randomised 
for labour induction with either oral misoprostol at a dose of 20mcg 2-hourly up to a 
maximum of 4-doses, or with intravenous oxytocin according to the WHO protocol. 
Main outcome measures: Induction to delivery interval; maternal complications and 
early neonatal outcomes.
Results: The overall induction success rates in the misoprostol arm was 81% versus 
83% in the oxytocin arm (P=0.447). The mean induction to vaginal delivery interval 
in the misoprostol arm was 8.4 hours as compared to 9.45 hours in the oxytocin arm 
(P=0.116). The induction to active labour interval was similar in the two study arms. 
The mean induction to active labour in the misoprostol arm was 4.02 hours as versus 
4.51 hours in the oxytocin arm (P=0.223 ). Two women who had failed induction with 
misoprostol were augmented with oxytocin and delivered vaginally. The Caesarean 
section rates were 19% in the misoprostol arm and 17% in the oxytocin arm (P=0.447), 
which was not statistically significant.  The maternal outcomes were similar in the two 
study arms. Four women had tachysystole in the misoprostol arm, compared to three 
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in the oxytocin arm (P=0.253). In the misoprostol arm two women had hypertonus 
compared to three in the oxytocin arm (P=0.322).There was one case of hyperstimulation 
in the misoprostol arm and two in in the oxytocin arm. There were no differences in 
the foetal/ neonatal outcomes. No baby had an Apgar score of less than seven at one 
or five minutes. No baby was admitted to the New Born Unit in either of the two arms. 
There was no case of a still birth in either of the study arms. There was no significant 
difference in the passage of meconium between the two arms, 39% in the misoprostol 
arm and 35.7% in the oxytocin arm (P=0.755). The passage of meconium did not impact 
on the neonatal outcomes.
Conclusion: Oral misoprostol solution 20mcg 2-hourly is as safe and effective as the 
standard intravenous oxytocin for labour induction in women presenting with pre-
labour rupture of membranes at term at the Kenyatta National Hospital.
INTRODUCTION
When pre-labour rupture of membranes (PROM) 
occurs at term, it can be managed either actively by 
prompt induction of labour or expectantly. Among 
different authors prompt induction can mean waiting 
2 to 12 hours after membranes rupture, whereas 
expectant management may refer to no induction, 
but more commonly means induction from 24 to 96 
hours (1).  
 Intravenous oxytocin has been the standard 
induction agent in PROM at term (12).
 Misoprostol, a synthetic prostaglandin E1 (PGE1) 
analogue was marketed from 1988 primarily for the 
prevention and treatment of peptic ulcer disease 
caused by non-steroidal anti-inflammatory drugs, 
but was noted to have uterotonic side effects. Further 
research revealed it to induce myometrial contractions 
as well as produce cervical ripening.
 In the past decade, several studies have been 
carried out on misoprostol for the induction of labour 
for various indications including PROM at term (2-6).
 The Cochrane Database of Systematic Reviews 
2009, gathered data from 56 studies with 11,590 
women on the administration of oral misoprostol for 
labour induction (7). They assessed oral misoprostol 
compared to placebo, vaginal dinoprostone, 
intra-cervical dinoprostone, intravenous oxytocin 
and vaginal misoprostol. The comparison with 
intravenous oxytocin group: - Eight trials including 
1026 women have compared oral misoprostol with 
intravenous oxytocin. Five studies used 100 mcg 
(818 women), two studies used 50 mcg (178 women) 
and one used 20 mcg solution (30 women). The 
study comparing 20mcg oral misoprostol solution 
with intravenous oxytocin showed no statistically 
significant difference in reported outcomes of vaginal 
delivery not achieved within 24 hours (RR 0.7 95% 
C.I, 0.3-1.65), or Caesarean delivery rate (RR 0.57, 95% 
C.I. 0.22-1.50). Meconium staining of the liquor was 
seen more frequently in the misoprostol group (RR 
1.72, 95% CI 1.08 to 2.74), but this was not reflected 
in significant differences in any adverse foetal or 
neonatal outcomes. There was no difference in the 
rate of uterine hyperstimulation syndrome. The data 
concluded that oral misoprostol is an effective agent 
for induction of labour with advantages over other 
agents or routes of induction. 
 However, most of these studies have been 
carried out in developed world where there are better 
resources for monitoring of labour. In the developing 
countries (including Kenya), resource constraints 
in the majority of the maternity units leads to less 
than optimal monitoring of induced labour (i.e, not 
having one–to-one care). Labour outcomes may thus 
vary from unit to unit, country to country depending 
on the availability of resources. Therefore there is a 
need to determine the effectiveness and safety of oral 
misoprostol solution at the KNH, a limited resource set 
up. If the safety of low dose oral misoprostol is realised 
at the KNH’s maternity unit, then benefits such as its 
low cost, easy storage (does not require refrigeration 
unlike oxytocin), and ease of administration can be 
utilised. The results can also be up scaled for use in 
our resource constrained country.
 We report here the results of a randomised clinical 
trial evaluating efficacy and safety of oral misoprostol 
solution 20mcg administered 2-hourly, as compared to 
the standard intravenous oxytocin in labour induction 
in mothers admitted to Kenyatta National Hospital’s 
(KNH) labour ward with a diagnosis of pre-labour 
rupture of membranes at term.
Research Question: Is oral 20mcg solution misoprostol 
administered 2-hourly as effective and as safe as the 
standard intravenous oxytocin in labour induction 
in women with pre-labour rupture of membranes at 
term at the Kenyatta National Hospital?
Hypothesis: Oral misoprostol solution administered at 
2-hourly intervals is not as effective and a safe as the 
standard intravenous oxytocin in labour induction 
in women with pre-labour rupture of membranes at 
term at the Kenyatta National Hospital.
The broad objective:To determine the effectiveness 
and safety of oral misoprostol solution administered 
2-hourly as compared to the standard intravenous 
oxytocin in labour induction in patients with pre-
labour rupture of membranes at term at the Kenyatta 
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The Specific objectives: to compare the induction to 
delivery intervals in the two study arms; to compare 
the prevalence of maternal complications in both 
labour induction regimens; to compare the early 
neonatal outcomes in both induction regimens.
Study population: The study population consisted of 
women presenting to the labour ward of Kenyatta 
National Hospital (KNH) with pre-labour rupture 
of membranes of four or more hours at term. They 
included those who had been on antenatal follow up 
at the KNH as well as those who have been referred 
from other clinics.
Study design: This was an unblinded randomised 
clinical trial designed to compare the effectiveness 
and safety of oral misoprostol solution administered 
2-hourly to the standard intravenous oxytocin in 
labour induction for pre-labour rupture of membranes 
at term. 
Study procedures: All women presenting to KNH`s 
labour ward admission desk between August and 
September 2009, with a history suggestive of PROM, 
were examined to confirm a diagnosis of PROM, a 
term gestation and the foetal well-being. 
 PROM was diagnosed on the based on any or 
all of the following:
A history of flow of liquor down the legs without 
being in labour; Active draining of liquor from the 
cervix with or without Valsalva manouvre; Pooling 
in the posterior fornix; Litmus test.
 The gestational age of 37-completed weeks was 
based on the following: -
Extrapolation of the last menstrual period; 
Extrapolation from the date of quickening; Palpation 
of the fundal height; Extrapolation of ultrasound 
findings in the first and second trimesters 
 Foetal well-being was assessed as follows: - 
Auscultation of the foetal heart using a fetoscope was 
done at the initial patient assessment, then repeated 
again after randomisation before the start of treatment, 
then every 30 minutes before the onset of active labour, 
every 30 minutes during active labour, and every five 
minutes during the second stage of labour. If foetal 
bradycardia, tachycardia or an irregular foetal heart 
developed, treatment was stopped and the condition 
managed by position change, oxygen and intravenous 
fluids with or without caesarean delivery depending 
on the stage of labour. Meconium staining of liquor 
was monitored. If meconium staining developed, 
treatment was stopped and the condition managed 
depending on the stage of labour. Cord prolapse was 
looked out for during vaginal examinations. If present 
it was to be treated as an emergency.
 Randomisation was based on a computer-
generated randomisation table. Computer-generated 
random numbers indicating the study allocation 
were printed on cards which were put in opaque 
envelopes and sealed. This was done by a person not 
directly involved in the study (the investigator and 
the research assistant midwives were not involved in 
this process). Consenting participants were assigned 
to induction method by opening the next sequentially 
numbered opaque sealed envelope. The envelope was 
opened by the investigator or the research assistant 
midwives in the presence of the participant. After 
opening the envelope, the investigator and the 
participant became aware of the treatment allocation. 
Thus, the study was a non-blinded clinical trial.
 Once the diagnosis of term PROM had been 
made and foetal well-being assured, participants 
were put through an eligibility check list of inclusion 
and exclusion criteria.
 The inclusion criteria included:Gestational 
age of 37 completed weeks and above, Rupture 
of membranes for four hours and above without 
labour, Singleton pregnancy in cephalic presentation, 
willingness to participate.
 The exclusion criteria included: Previous uterine 
surgery (Caeserian sections, myomectomy), Clinical 
diagnosis of Chorioamnionitis: (maternal fever[more 
than 38ºC plus any two of the following: maternal 
tachycardia, foetal tachycardia, uterine tenderness, 
offensive vaginal discharge), Unexplained vaginal 
bleeding, pre-eclampsia, Intrauterine growth 
retardation, Contraindications to prostaglandins 
eg asthma. Those in active labour, High parity 
(more than para 4), Multiple pregnancy, Placenta 
praevia, Diabetes mellitus, Rhesus isoimmunisation, 
Meconium stained liguor, Non-reassuring foetal 
status (meconium stained liquor, foetal tachycardia, 
foetal bradycardia, late decelerations), Unwillingness 
to participate.
 Those who were eligible for the study were 
counseled on the nature of the study by the 
investigator or the research assistant midwives. Those 
who accepted to participate were recruited and signed 
the informed consent form.
 Their socio-demographic information and 
obstetric history was obtained. The investigator or 
the research assistant mid wife then picked a sealed 
opaque envelope containing a randomly generated 
computer number, the envelope opened in the 
participant’s presence, and the participant assigned to 
either the misoprostol or the oxytocin arm as per the 
envelope. Before starting treatment, the participant 
was re-examined to check foetal well-being.
 Misoprostol solution was obtained by dissolving 
a 200mcg tablet in 200ml of boiled and cooled tap 
water to obtain a concentration of 1mcg per ml (8). 
The 200 ml of misoprostol solution was put in a 300 
ml container. This was done by the Chief Pharmacist 
of the KNH. Calibrated cups were used to measure 
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20ml (20mcg) of misoprostol solution which was 
administered to the participants in the misoprostol 
arm. The solution remains stable up to 24-hours after 
which it is discarded (9). 
 Misoprostol solution was administered orally at 
20mcg 2-hourly (8), for a maximum 4-doses or until 
there was established labour. Those not in active 
labour four hours after the fourth dose of misoprostol 
were considered failed induction and started on 
oxytocin. Augmentation with oxytocin was used if 
labour progressed at less than 1cm per hour after 
reaching 4cm in the absence of meconium-stained 
liquor, abnormal foetal heart rate or pathological 
molding. Oxytocin was administered as per the WHO 
protocol.
    The study participants were put on prophylactic 
antibiotics as per KNH`s protocol (if PROM at term 
was more than 18-hours, participants were put on 
oral erythromycin 500mg 6-hourly). Labour was 
monitored through the use of a partograph. In both 
groups Caesarian delivery was done for the standard 
obstetric indications. The progress of labour and the 
maternal and foetal outcomes were recorded in the 
questionnaires.
The outcome measures of the study:
A:  Primary outcome measures included: (1)Induction 
to vaginal delivery, (2) Vaginal delivery achieved, 
(3) Uterine hyperstimulation with foetal heart rate 
(FHR) changes, (4) Serious maternal morbidity 
or death (e.g. uterine rupture, admission 
to intensive care unit), (5) Serious neonatal 
morbidity (e.g. seizures, birth asphyxia , neonatal 
encephalopathy)  or perinatal death,
B: Secondary outcome measures included: 
(1) Oxytocin augmentation. (2) Uterine 
hyperstimulation without FHR changes; (3) 
Apgar score less than seven at five minutes; (4) 
Postpartum haemorrhage; (5) Any other maternal 
complications. 
The sample size (n) calculation:Using the null hypothesis, 
it is a two tailed (Z1 –α 12) study with a power of 
80% (Z1-β) (11).
Z1-α12  = (2-tailed) =1.96 
Z1-β = 80%power =0.84
δ1 = 6.4 (standard deviation of the misoprostol group)
δ2 = 6.5 (standard deviation of the oxytocin group)
μ1 = 12 (mean induction time of the misoprostol group) 
μ2 = 8 (mean induction time of the oxytocin group)
n = (Z1-α12+Z1-β )
2 × (δ12+δ22)
(μ1-μ2)2
n = (1.96 + 0.84 )
2 × (6.42 +6.52)
42
n =41
The sample size is calculated to be 41 participants 
for each group.
Ethical Review: The protocol was approved by the 
Kenyatta National Hospital/University of Nairobi 
Ethics Review Committee, and registered with the 
KNH Scientific Committee.
Data management: Data were collected using coded 
questionnaires. The raw data were verified to check 
for errors or omissions made while filling out the 
data entry form. Data were subsequently entered 
into a computer, processed and analysed using SPSS 
Statistics for windows, Version 18.0. Students t-test 
was used to test associations of parametric data; 
while Pearson`s chi-square test, Fishers exact and 
Mann-Whitney-U-tests were used for non-parametric 
statistics. Results were presented in frequency 
distribution and descriptive statistical tables.
RESULTS
Of the 83 enrolled pregnant women with pre-labour 
rupture of membranes at term, 41 were randomised 
to the misoprostol arm while 42 were randomised to 
the oxytocin arm.
 There were no differences in socio-demographic 
characteristics in the 2-study groups; with a median 
age of 24 years (interquartile range[IQR] 22-28),  a 
median of 12 years of education (IQR 10-17), and 
most were housewives (Table 1).
















Age years, Median, interquartile range(IQR) 24(22, 28) 24(22, 28)
Education years, Median, IQR 12(10,17) 12(10,17)
Occupation 
   Student 4(9.8%) 3(7.1%) 0.584
   Housewife 13(31.7%) 14(33.3%) 0.475
   Self-employed 12(29.3%) 8(19%) 0.132
   Civil-servant 6(14.6%) 8(19%) 0.384
   Private 6(14.6%) 9(21.4%) 0.269
The obstetric characteristics of the 2-study populations were similar. The median gestational age was 38 
weeks (IQR 38-40), they had a median Bishop’s score of 4 (IQR 4-5) and most of the women were nulliparous 
(Table 2).
Table 2
Obstetric characteristics of the study population (N/%)
Median, IQR, N% 
Characteristic Misoprostol (N= 41) Oxytocin (N= 42) P
Parity
 0 18(43.9%) 17(42.9%) 0.254
 1 17(41.5%) 16(40.2%) 0.37
 2 4(9.8%) 6(12.3%) 0.398
 3 2(4.9%) 3(4.6%) 0.376
Median gestation weeks, IQR 38(38,40) 38(38,40)
Median Bishop’s score, IQR 4(4,5) 4(4,5)
The mean duration of PROM in the misoprostol arm was 6.13 hours compared to 8.21 hours in the oxytocin 
arm, this was not statistically significant (Table 3).
Table 3
Duration of PROM by study group
Misoprostol Oxytocin
Duration of PROM (hrs) N=41 N=42 P
4-8 23 19 0.238
8-12 15 190.379
Above 12 3 4 0.253
The mean duration of PROM (hrs) 6.13 8.21 0.149
There were no statistically significant differences in the induction to vaginal delivery intervals between the 
two study arms. The mean induction to vaginal delivery interval in the misoprostol arm was 8.4 hours as 
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compared to 9.45 hours in the oxytocin arm (P=0.116 ). The mean induction to active labour in the misoprostol 
arm was 4.02 hours as compared to 4.51 hours in the oxytocin arm (P=0.223) (Table 4). 
Table 4
Summary statistics on duration of induction by study group                                                                                                  
Duration (hours) Misoprostol (N= 41) 
Mean (1 SD)
Oxytocin (N= 42) 
Mean (1 SD)
P
Induction to active labour 4.02(1.52) 4.51(1.93) 0.226
Induction to second stage of labour 8.38(2.31) 9.03(3.11) 0.335
Induction to delivery time 8.4(2.35) 9.45(3.04) 0.116
There were eight women with failed induction in the 
misoprostol arm compared to seven in the oxytocin 
arm (P= 0.76). There were no significant differences in 
the modes of delivery in the two arms, with 35  women 
(85%) in the misoprostol arm delivering vaginally 
compared to 36 women (83.3%) in the oxytocin arm 
(P= 0.447). Oxytocin augmentation was given to two 
(4.9%) of the women in the misoprostol arm. The two 
women who had failed induction with misoprostol 
were augmented with oxytocin and delivered 
vaginally. They were analysed as failed induction in 
the misoprostol arm. The Caesarean section rates were 
19% in the misoprostol arm and 17% in the oxytocin 
arm (P= 0.447), which was not statistically significant. 
Three mothers were delivered by Caesarean due to 
failed induction in the misoprostol group compared 
to three in the oxytocin group (P= 0.473). There were 
three Caesarean deliveries in the misoprostol group 
due to non reassuring foetal status compared to 
four in the oxytocin arm for the same indication (P= 
0.474) (Table 5).
Table 5
Outcome of labour induction by study group 
Outcome Misoprostol N=41) 
No.(%)




Success of induction  
     Succeeded 33(80.5) 35(83.3) 0.76
     Failed  8(19.5) 7(16.7) 0.65
Mode of delivery
     Vaginal 35(81) 35(83) 0.447
     Caesarian section 6(19) 7(17) 0.447
Uterine contraction abnormalities were not statistically 
significant between the two arms.  Four women had 
tachysystole in the misoprostol arm compared to 
three in the oxytocin arm (P=0.253). In the misoprostol 
arm two women had hypertonus compared to three 
in the oxytocin arm (P=0.322).There was one case of 
hyperstimulation in the misoprostol arm and two in 
in the oxytocin arm (P=0.316). There were no cases of 
uterine rupture, postpartum haemorrhage, retained 
placenta or maternal death in either of the two arms 
(Table 6).
Table 6






Tachysystole 4 3 0.253
Hypertonus 2 3 0.327
Hyperstimulation syn 1 2 0.316
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No baby had an Apgar score of less than seven at ine 
or five minutes. Eleven neonates had Apgar scores 
of seven to eight at five minutes in the misoprostol 
group compared to 9 in the oxytocin group (P=0.286). 
Thirty neonates had Apgar scores of nine to ten at 
five minutes in the misoprostol group compared to 
33 in the oxytocin group (P=0.229). Hence there were 
no statistically significant differences in Apgar scores 
in the two study groups. No baby was admitted to 
the New Born Unit in either of the two arms. There 
was no case of a still birth in either of the study arms 
(Table 7).
Table 7






Infants Apgar score at 1min
    0-6 0 0
    7-8 28 24 0.693
    9-10 13 18 0.628
Infants Apgar score at 5 min
    0-6 0 0
    7-8 11 9 0.286
    9-10 30 33 0.229
Meconium passed(N/%)
    Yes 16(39) 15(35.7) 0.755
    No 25(61) 27(64.3) 0.755
Birth weight (Mean/SD) 3103.9(382) 3184.52(372.12) 0.3330
DISCUSSION
In a randomised, unblinded study of women 
presenting with pre-labour rupture of membranes 
at term at the Kenyatta National Hospital, we 
assessed the safety and effectiveness of induction of 
labour using oral misoprostol solution administered 
two-hourly compared to the standard intravenous 
oxytocin, and found no difference in duration of 
labour, mode of delivery, maternal or neonatal 
outcomes. These data indicate that oral misoprostol 
solution two-hourly, is as safe and effective as 
intravenous oxytocin for induction of labour among 
women at term with PROM. Our findings are in 
agreement with other data, including a systematic 
Cochrane review (7).
 The mean induction to vaginal delivery interval 
in the misoprostol arm was 8.4 hours as compared 
to 9.45 hours in the oxytocin arm (P=0.116 ). This 
finding is in keeping with other studies done before. 
In the Cochrane Review 2009, six trials comparing 
oral misoprostol to oxytocin, involving 758 women 
with PROM were reviewed (7). Overall there were 
no statistically significant differences in induction to 
vaginal delivery interval (P=0.86).
 The mode of delivery was similar in the two 
arms with 81% of the women in the misoprostol arm 
with vaginal births compared to 83% in the oxytocin 
arm (P=0.447). Caesarean section deliveries were 
17% and 19% in the misoprostol and oxytocin arms 
respectively (P=0.447).In the Cochrane review (7), 
there were no statistically significant differences in 
the modes of delivery between oral misoprostol and 
oxytocin for labour induction in term PROM in the 
six trials reviewed. However, the Caesarean section 
rates were lower ranging from 4.9-13.2 %. This could 
be attributed to the fact that these studies were carried 
out in the developed countries where there is intensive 
electronic monitoring of labour. This study was carried 
out in a limited resource set up where facilities such 
as foetal scalp blood sampling for foetal acaedemia 
are currently not available. This could explain the 
fact that 7 out of 12 Caesarean deliveries done in this 
study were due to non-reassuring foetal status.
 The maternal outcomes were similar in the two 
study arms. There were no cases of uterine rupture, 
postpartum haemorrhage, retained placenta or 
maternal death in either of the two arms. Uterine 
contraction abnormalities were not statistically 
significant between the two arms. There was one 
case of hyperstimulation in the misoprostol arm and 
two in in the oxytocin arm (P=0.316). This compares 
favorably with similar studies in the Cochrane Review 
(7, P=0.73).
 There were no statistically significant differences 
in the foetal/neonatal outcomes in the two study 
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arms. No baby had an Apgar score of less than seven 
at one or five minutes, no baby was admitted to the 
New Born Unit, and there was no case of a still birth 
in either of the study arms. There was no significant 
difference in the passage of meconium between the 
two arms, 39% in the misoprostol arm and 35.7% in 
the oxytocin arm (P = 0.755). Similar studies in the 
Cochrane review (7) have had a similaroutcomes 
regarding passage of meconium (P=0.098).The 
passage of meconium did not impact on the neonatal 
outcomes.
 This study comparing oral misoprostol and 
oxytocin used a low dose of oral misoprostol 20 
mcg administered two-hourly. This low dose of 
misoprostol could account for the lack of any severe 
adverse event in this study. This dose appears to be 
safe and effective for labour induction in women with 
pre-labour rupture of membranes at term.
 The strength of this study is that it was a 
randomised clinical trial, there was no loss to follow-
up, and then study participants adhered to treatment. 
None of the study participants requested a different 
arm after allocation to a study arm.
 The study is limited by the fact that it was an 
unblinded clinical trial, thus there is a possibility of 
bias in clinical decision making and in the assessment 
of outcomes. Another limitation is that there are no 
commercially available 20 mcg misoprostol tablets. To 
get 20 mcg used in this study, a 200 mcg misoprostol 
tablet was dissolved in 200 ml of water to achieve a 
concentration of 1mcg/ml, thus there is no guarantee 
that each of the 20 ml of the solution contained 20mcg 
misoprostol. 
In conclusion, oral misoprostol solution administered 
at 20mcg two-hourly is as effective and as safe as 
intravenous oxytocin for labour induction in women 
presenting with pre-labour rupture of membranes at 
term at the Kenyatta National Hospital.
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